Abbott Laboratories (NYSE:ABT) Reaches New 52-Week Low - Time to Sell?

Key Points

• Shares of Abbott reached a new 52-week low (as low as $86.16, last $87.18) on heavy volume; several analysts have cut price targets but the consensus remains a Moderate Buy with an average target of $119.43.
• Abbott posted a slight quarterly EPS beat ($1.15 vs. $1.14 est.) with revenue up 7.8% year-over-year and issued FY 2026 guidance of $5.38–$5.58 in EPS (analysts average ~5.48).
• The company declared a quarterly dividend of $0.63 (≈2.9% yield) and a director purchased 10,000 shares at $92.65, indicating ongoing shareholder returns and at least one insider adding to their position.

Shares of Abbott Laboratories (NYSE:ABT - Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $86.16 and last traded at $87.1760, with a volume of 17186453 shares. The stock had previously closed at $87.54.

Wall Street Analyst Weigh In

ABT has been the subject of several recent analyst reports. TD Cowen decreased their price target on Abbott Laboratories from $137.00 to $115.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Royal Bank Of Canada cut their price objective on Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating for the company in a report on Friday, April 17th. UBS Group cut their price objective on Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating for the company in a report on Monday, April 20th. Evercore cut their price objective on Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating for the company in a report on Friday, April 17th. Finally, Daiwa Securities Group lowered Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price objective for the company. in a report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $119.43.

Abbott Laboratories Stock Down 0.4%

The company has a fifty day moving average of $103.83 and a 200 day moving average of $115.68. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market cap of $151.84 billion, a P/E ratio of 24.42, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the previous year, the company posted $1.09 earnings per share. Abbott Laboratories's revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories's payout ratio is currently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares of the company's stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the business's stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares of the company's stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last ninety days. 0.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Abbott Laboratories

Hedge funds have recently made changes to their positions in the business. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $26,000. Institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.